Funding for this research was provided by:
Text and Data Mining valid from 2018-04-06
Received: 26 October 2017
Accepted: 22 March 2018
First Online: 6 April 2018
: SG works in the laboratories overseen by AA at SR-TIGET and is responsible for the performance and technical supervision of cellular assays conducted as part of the follow-up of patients with ADA-SCID treated with gene therapy.MK was an employee of GlaxoSmithKline, Brentford, Middlesex, UK at the time of the study. Currently an employee of Orchard Therapeutics.
: Ethical approval for the Strimvelis registry has been given by the San Raffaele Hospital Ethics Committee in Italy and will also be obtained where it is required in patients’ own countries. All patients included in the registry are required to provide informed consent to participate.
: Not applicable
: MPC is the Principal Investigator (PI) of the ADA-SCID registry trial. AA is the PI of the ADA-SCID gene therapy trial and other clinical trials sponsored by GlaxoSmithKline (GSK) which are part of the alliance between Ospedale San Raffaele-Telethon and GSK. SG, MG, AC and SZ declare no competing interest. MD is an employee of Pharmaceutical Product Development. HS-F, NG, JI, BC, RB, JA and PN are employees of GlaxoSmithKline. MK is an employee of Orchard Therapeutics.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.